Abstract Background: The Glucagon Like Peptide 1 (GLP1) recep-tor agonists are a new class for treatment of both type 2 diabetes and obesity. Aim of Study: To evaluate efficacy of GLP1 analogues in both weight reduction and glycemic control in obese Egyptians with and without diabetes. Patients and Methods: This intervention study was con-ducted from August 2017 to August 2018. Total of 40 patients were divided into 3 groups: Obese group, obese group with diabetes & obese group with diabetes after failure to lose 10% of their initial weight after bariatric surgery. Clinical data were collected, anthropometric measures and laboratory investigation included fasting blood glucose and HbA1c in the beginning and every 3 months for a year were done. Results: This study showed statistically significant body weight and BMI reduction in all groups, there was statistically significant reduction of fasting blood glucose, and HBA1c in the 2nd & 3rd group. Conclusion: GLP1 analogues are effective in treatment of obese patients with and without diabetes.
ELBANA, M.D., K. A. (2019). Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes. The Medical Journal of Cairo University, 87(September), 3205-3208. doi: 10.21608/mjcu.2019.65613
MLA
KHALED A. ELBANA, M.D.. "Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes". The Medical Journal of Cairo University, 87, September, 2019, 3205-3208. doi: 10.21608/mjcu.2019.65613
HARVARD
ELBANA, M.D., K. A. (2019). 'Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes', The Medical Journal of Cairo University, 87(September), pp. 3205-3208. doi: 10.21608/mjcu.2019.65613
VANCOUVER
ELBANA, M.D., K. A. Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes. The Medical Journal of Cairo University, 2019; 87(September): 3205-3208. doi: 10.21608/mjcu.2019.65613
)
View on SCiNiTO